ContraFect Corporation ContraFect Corporation Nasdaq: CFRX

Navigate ContraFect Corporation

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Lysins
    • Amurins
    • Publications / Posters
    • Video Library
  • Pipeline
    • Overview
    • Exebacase
    • CF-370
    • Gram-negative Lysins
    • Amurins
  • Investors & Media
    • Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Analyst Coverage
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Press Releases

Investors & Media

  • Home
  • Investors & Media
  • News / Events
  • Press Releases
Investors & Media

Investors & Media

  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • Events
    • Email Alerts
  • Presentations
  • Company Information
  • Financial Information
  • Analyst Coverage
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

April 4, 2019

ContraFect Announces CEO Transition

April 2, 2019

ContraFect to Present at the Bacteriophage Therapy Summit

March 21, 2019

ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

March 14, 2019

ContraFect to Present at the Oppenheimer 29th Annual Healthcare Conference

March 13, 2019

ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens

March 4, 2019

ContraFect Announces Oral Presentation at the 2019 Gordon Research Conference on Mechanisms and Application: Realizing the Potential of Antimicrobial Host Defense Peptides for Human and Veterinary Medicine

February 13, 2019

ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program

January 17, 2019

ContraFect’s Exebacase (CF-301) Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including  Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study

January 7, 2019

ContraFect to Present at Biotech Showcase 2019

December 20, 2018

RSS
  • « Previous
  • 1...
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • ...22
  • Next »
© 2022 ContraFect Corporation. All Rights Reserved.
Copyright Privacy Policy Expanded Access Policy Disclaimer Site Map
LinkedIn Twitter